Dr Reddy's Laboratories stated that certain batches of semaglutide were found to be out of specification due to an issue associated with the active pharmaceutical ingredient (API) used in the product.

Dr Reddy''s Laboratories announced a delay in commercial supplies of its anti-diabetic semaglutide due to ingredient issues. Patient safety is not affected.

Dr Reddy's informed stock exchanges that certain batches of semaglutide were found to be out of specification due to an issue ...

Dr Reddy's Laboratories tumbled 6.29% to Rs 1,263.90 after the company said commercial supplies of certain batches of its semaglutide product will be delayed following a quality-related issue ...

Brokerage firm Jefferies, in a note dated July 1, stated that it is stretching its estimates for two key growth drivers for ...

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to ...

Dr Reddy's Laboratories said that commercial production of semaglutide has been delayed due to an active ingredient-related issue in certain batches ...

Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a ...

Vishal Manchanda, Pharma Analyst at Systematix Group, said semaglutide is a technically complex peptide product, making ...

For smaller mutuals without proprietary broker-facing technology, eDocs certification is the most accessible way to compete ...

Amazon (which owns MX Player and Prime Video), Netflix, and Meta have historically retained tight control over audience data ...

"Despite headwinds in Q4 FY26, we maintain a positive view on the company as the majority of the impact was one-off in nature ...